Back to Search
ALLAN HAYNES, MD
MD
Trauma Surgery Physician
NPI: 1760581805IndividualAccepts Medicare
Specialties, Licenses & Credentials
Surgery Physician
Surgery
Code: 208600000X
N1675(TX)
Trauma Surgery PhysicianPrimary
Surgery — Trauma Surgery
Code: 2086S0127X
N1675(TX)
CMS Specialties
PrimaryGENERAL SURGERY
Education
TEXAS TECH UNIVERSITY HEALTH SCIENCE CENTER SCHOOL OF MEDICINE
Class of 2000
Research & Publications (20)
Syndecan 1 shedding contributes to Pseudomonas aeruginosa sepsis.
PMID 16299282·Infect Immun·2005
7-preclinical
Clinical outcome of patients with docetaxel-resistant hormone-refractory prostate cancer treated with second-line cyclophosphamide-based metronomic chemotherapy.
PMID 19365737·Med Oncol·2010
4-observational
Assigned versus random, countermeasure-like responses in the p300 based complex trial protocol for detection of deception: task demand effects.
PMID 19543970·Appl Psychophysiol Biofeedback·2009
8-other
Long-term follow-up of 233 patients with hairy cell leukaemia, treated initially with pentostatin or cladribine, at a median of 16 years from diagnosis.
PMID 19344416·Br J Haematol·2009
8-other
A surgical safety checklist to reduce morbidity and mortality in a global population.
PMID 19144931·N Engl J Med·2009
4-observational
Identification of the reactive cis,mer isomer of [Ir(CO)2I3Me]-: relation to the mechanism of iridium-catalyzed methanol carbonylation.
PMID 19061388·Inorg Chem·2009
8-other
Involvement of macroautophagy in the caspase-independent killing of Burkitt lymphoma cell lines by rituximab.
PMID 19183195·Br J Haematol·2009
8-other
Transitional cell carcinoma due to chronic UroLume stent irritation.
PMID 19193405·Urology·2009
5-case
Outcome of BEAM-autologous and BEAM-alemtuzumab allogeneic transplantation in relapsed advanced stage follicular lymphoma.
PMID 18318762·Br J Haematol·2008
4-observational
Dose-intensive chemotherapy with growth factor or autologous bone marrow or stem-cell transplant support in first-line treatment of advanced or metastatic adult soft tissue sarcoma: a clinical practice guideline.
PMID 18454188·Curr Oncol·2008
8-other
Internalisation of uncross-linked rituximab is not essential for the induction of caspase-independent killing in Burkitt lymphoma cell lines.
PMID 18766972·Leuk Lymphoma·2008
8-other
Dose-intensive chemotherapy with growth factor or autologous bone marrow/stem cell transplant support in first-line treatment of advanced or metastatic adult soft tissue sarcoma: a systematic review.
PMID 18224666·Cancer·2008
1-meta
The use of erythropoiesis-stimulating agents in patients with non-myeloid hematological malignancies: a systematic review.
PMID 18629499·Ann Hematol·2008
1-meta
Autologous stem cell transplantation in elderly patients (> or =60 years) with diffuse large B-cell lymphoma: an analysis based on data in the European Blood and Marrow Transplantation registry.
PMID 18838474·Haematologica·2008
8-other
IVE (ifosfamide, epirubicin and etoposide) is a more effective stem cell mobilisation regimen than ICE (ifosphamide, carboplatin and etoposide) in the context of salvage therapy for lymphoma.
PMID 18353164·Br J Haematol·2008
4-observational
Meta-analysis of ifosfamide-based combination chemotherapy in advanced soft tissue sarcoma.
PMID 18313854·Cancer Treat Rev·2008
1-meta
A meta-analysis and systematic review of thalidomide for patients with previously untreated multiple myeloma.
PMID 18381234·Cancer Treat Rev·2008
1-meta
An estimation of the global volume of surgery: a modelling strategy based on available data.
PMID 18582931·Lancet·2008
8-other
A paraneoplastic manifestation of metastatic breast cancer responding to endocrine therapy: a case report.
PMID 19087318·World J Surg Oncol·2008
5-case
A requirement for calcium in the caspase-independent killing of Burkitt lymphoma cell lines by Rituximab.
PMID 18544085·Br J Haematol·2008
8-other
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 3509 22ND ST
LUBBOCK, TX 79410 - Phone
- (806) 799-7928
Quick Facts
- NPI
- 1760581805
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 2
- Locations
- 1
- Years in Practice
- 26
- Publications
- 20
Are you this provider?
Claim Your Profile